On May 23, the NMPA official website revealed that Aripiprazole (Aripiprazole long-acting intramuscular injection) developed by Otsuka Pharmaceutical to treat schizophrenia was approved for marketing.
US-based Lyndra Therapeutics has revealed plans to develop a once-monthly oral contraceptive that will deliver a continuous dose of estrogen and progestin over multiple weeks.